ArticleMicrobiology spectrum2025
Epidemiological changes of
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Etiological characterization of acute respiratory tract infections and associated co-infections using Biofire respiratory 2.1 Plus panel.BMC infectious diseases · 2026Article
- Epidemic Pattern Changes in Influenza A and B and Mycoplasma pneumoniae Pediatric Respiratory Infections During and After the COVID-19 Pandemic Restrictions in Northwest China.Current microbiology · 2026Article
- Macrolide Resistance ofInfection and drug resistance · 2026Article
- Epidemiology, temporal trends and co-infection of 13 respiratory pathogens in 32,125 children: a 3-year retrospective study.Frontiers in pediatrics · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Prevalence of Macrolide-Resistant Mycoplasma pneumoniae Infections After the COVID-19 Pandemic in Southern Italy, 2023-2025.Infectious diseases and therapy · 2025Article
- Six-year epidemiological dynamics of human respiratory syncytial virus infections in children in central China (2019-2024): pandemic suppression, 2023 resurgence, and immune debt effect.Frontiers in cellular and infection microbiology · 2025Article
- Positive rates ofFrontiers in microbiology · 2025Article
- High-altitude immune remodeling in children withFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies characterizing the epidemic of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.